Mölndal, Sweden

Jonas Brånalt

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Mölndal, SE (2012)
  • Gothenberg, SE (2024)

Company Filing History:


Years Active: 2012-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jonas Brånalt

Introduction

Jonas Brånalt is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work has the potential to impact various medical conditions.

Latest Patents

Jonas Brånalt's latest patents include innovative compounds such as N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides. These compounds are designed to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions. Additionally, he has developed pharmaceutical compositions comprising these compounds and methods for their manufacturing. Another significant invention relates to novel pharmaceutically useful compounds that act as competitive inhibitors of trypsin-like serine proteases, particularly thrombin. These compounds are intended for use as medicaments and are accompanied by synthetic routes for their production.

Career Highlights

Jonas Brånalt is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on the research and development of innovative therapeutic solutions. His contributions have been instrumental in advancing the company's pharmaceutical portfolio.

Collaborations

Jonas collaborates with talented professionals, including Maria Johansson and Anneli Nordqvist. Their teamwork enhances the research efforts and fosters innovation within their projects.

Conclusion

Jonas Brånalt's innovative work in pharmaceuticals showcases his dedication to improving medical treatments through his patented inventions. His contributions are paving the way for advancements in therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…